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Abstract
Background:  Congenital  sucrase--isomaltase  deﬁciency  (CSID)  is  an  autosomal  recessive  disease
characterized  by  absent  sucrase  activity  with  variable  decrease  in  isomaltase  activity.  The
prevalence of  CSID  in  Portuguese  population  is  unknown  and  there  are  few  reported  cases.
Case report:  We  report  the  case  of  a  six-month-old  male  infant  admitted  for  chronic  profuse
diarrhea and  failure  to  thrive  that  began  after  food  diversiﬁcation.  The  investigation  showed
that he  had  CSID.  The  therapeutic  option  was  the  addition  of  baker’s  yeast  to  the  diet  which
was followed  by  complete  resolution  of  symptoms  and  excellent  weight  recovery.
Discussion:  This  case  highlights  the  relevance  of  clinical  observation  and  awareness  in  a  condi-
tion where  diagnosis  is  essentially  clinical.  The  available  therapeutic  options  are  addressed  with
pragmatic use  of  baker’s  yeast.
©  2014  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
PALAVRAS-CHAVE
Deﬁciência  congénita
Déﬁce  congénito  de  sacarase-isomaltase:  relato  de  um  casode
sacarase-isomaltase;
Resumo
Introduc¸ão:  O  déﬁce  congénito  de  sacarase-isomaltase  é  uma  doenc¸a  autossómica  recessiva
caraterizada  pela  ausência  da  atividade  da  sacarase  e  diminuic¸ão  variável  da  atividade  daSacrosidase;
Fermento;
Saccharomyces
cerevisiae
isomaltase.  A  prevalência  desta  patologia  na  populac¸ão  portuguesa  é  desconhecida  e  há  poucos
casos divulgados.
Abbreviations: CSID, congenital sucrase--isomaltase deﬁciency; DNA, deoxyribonucleic acid; IgE, immunoglobulin; EPCR, polymerase
hain reaction; SI, sucrase--isomaltase.
∗ Corresponding author.
E-mail address: ritasantossilva@gmail.com (R. Santos-Silva).
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341-4545/© 2014 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier España, S.L.U. All rights reserved.
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Relato  de  caso:  Lactente  masculino  de  6  meses,  internado  para  estudo  de  diarreia  crónica
profusa coincidente  com  o  início  da  diversiﬁcac¸ão  alimentar  e  associada  a  má  evoluc¸ão  pon-
deral. A  investigac¸ão  mostrou  tratar-se  de  uma  deﬁciência  congénita  de  sacarase-isomaltase.
A medida  terapêutica  escolhida  foi  a  adic¸ão  de  fermento  de  padeiro  na  dieta,  com  resoluc¸ão
da sintomatologia  e  excelente  recuperac¸ão  ponderal.
Discussão:  Discute-se  a  importância  de  uma  elevada  suspeic¸ão  clínica  numa  patologia  cujo
diagnóstico  é  essencialmente  clínico  e  também  as  opc¸ões  terapêuticas  disponíveis,  com  ênfase
no uso  do  fermento  de  padeiro.
© 2014  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos
os direitos  reservados.
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thrive.  He  is  the  only  child  of  young,  healthy  and  non-1. Introduction
Congenital  sucrase--isomaltase  deﬁciency  (OMIM  #222900)
is  caused  by  homozygous  or  compound  heterozygous  muta-
tion  in  the  SI  gene,  which  encodes  sucrase--isomaltase  on
chromosome  3q26.
Sucrase--isomaltase  is  an  enterocyte-speciﬁc  small  intes-
tine  brush-border  membrane  disaccharidase.  It  is  required
for  hydrolysis  of  sucrose  and  some  starches.  Upon  inges-
tion  of  disaccharides  and  oligosaccharides,  the  failure  to
breakdown  sucrose  into  fructose  and  glucose  results  in
osmotic-fermentative  diarrhea.
CSID  is  the  most  common  congenital  disorder  of  car-
bohydrate  metabolism.  Its  estimated  prevalence  in  North
America  and  Europe  ranges  from  0.05%  to  0.2%,1 although
this  diagnosis  is  believed  to  be  frequently  missed.
Onset  usually  occurs  during  infancy  after  weaning
from  breast  milk  or  lactose-only  formula  onto  foods  con-
taining  sucrose  or  starch.  Clinical  manifestations  include
osmotic-fermentative  diarrhea,  abdominal  distension  and
discomfort,  ﬂatulence,  vomiting  and  diaper  rash.2 Severe
symptoms  may  lead  to  failure  to  thrive,  dehydration  and
malnutrition.  Adolescents  and  adults  may  present  with  signs
of  ‘irritable  bowel  syndrome’.  Carbohydrates  result  in  a
dose-dependent  acceleration  of  colonic  transit3 and  there-
fore  symptoms  may  only  occur  with  the  ingestion  of  large
amounts  of  sucrose.2
CSID  is  a  heterogeneous  disorder.  Identiﬁed  mutations
lead  to  a  range  of  posttranslational  defects  resulting  in  an
absence  of  sucrase  activity  and  varying  degrees  of  isoma-
ltase  deﬁciency.  Heterozygotes  have  intermediate  enzyme
values  and  are  usually  asymptomatic  in  adulthood,  but  may
have  mild  symptoms  in  infancy.
Several  tests  can  be  used  to  diagnose  CSID,  with  measure-
ment  of  intestinal  disaccharides’  activities  being  the  gold
standard.2 It  will  show  complete  or  almost  complete  lack  of
sucrase/isomaltase  activity  with  normal  lactase  activity  and
normal  villous  architecture.
The  hydrogen  breath  test  is  a  non-invasive  method  for
detecting  carbohydrate  malabsorption.  This  test  is  based
on  the  fact  that  unabsorbed  sugar  is  converted  to  hydro-
gen  gas  by  colonic  bacteria,  which  is  eliminated  via  expired
air.3 However,  it  is  not  speciﬁc  for  the  diagnosis  of  CSID
and  false-negative  results  may  be  obtained  because  of  many
factors  affecting  the  hydrogen  production.3 An  evolution  of
the  hydrogen  breath  test  is  the  measurement  of  isotope-
c
e
oabeled  CO2 in  breath  using 13C  or 14C  by  mass  spectrometers.
 sucrose  breath  test  for  screening  and  conﬁrmation  of
SID  using  a  novel  non-invasive 13C-sucrose  labeled  sub-
trate  has  been  developed  and  validated,  and  is  an  accurate
nd  speciﬁc  noninvasive  conﬁrmatory  test  for  CSID.4 How-
ver,  obtaining  breath  samples  may  be  difﬁcult  in  small
hildren.  Evidence  of  unabsorbed  sugars  (Clinitest®) also
rovides  indirect  evidence  of  poor  carbohydrate  digestion.
owever,  Clinitest® looks  for  reducing  sugars  in  the  stool
nd  sucrose,  as  stated  later,  is  not  in  its  natural  form  a
educing  sugar.  Therefore,  negativity  of  Clinitest  is  not  actu-
lly  a  false  negative  test;  it  is  a  true  negative  test  in  the
ontext  of  Sucrase  Isomaltase  deﬁciency  when  looking  for
ucrose.
Fecal  carbohydrates  can  also  be  measured  by  high-
erformance  liquid  chromatography,  but  this  test  has  some
alse  negatives  due  to  transport  times  required,  that  allow
onsumption  of  sugars  by  fecal  ﬂora.  Other  diagnostic  meth-
ds  available  include  the  glycemic  curve  and  stool  tests
fecal  pH  lower  than  5.5  with  or  without  reducing  sugars
ithout  steatorrhea).3,5 Molecular  genetic  test  for  mutation
n  SI  gene  is  also  available.
The  mainstay  of  treatment  is  a  lifelong  adherence  to
 sucrose-  and  starch-restricted  diet.5 Effective  enzyme
eplacement  with  whole  yeast  cells  has  been  reported.6
uriﬁed  yeast  enzyme,  sacrosidase,  is  a  highly  effective
herapy  and  allows  a  normal  diet.4
CSID’s  prognosis  is  good.  Affected  patients  tend  to  expe-
ience  spontaneous  improvement  of  their  symptoms  with
ge,  because  colonic  bacteria  become  able  to  metabo-
ize  non  absorbed  carbohydrates  into  organic  acids  (lactic
cid  and  short  chain  fatty  acids),  most  of  which  are  then
bsorbed.3 Patients  learn  to  identify  their  tolerance  limits,
ut  remain  exposed  to  occasional  episodes  of  diarrhea  when
hey  ingest  amounts  of  carbohydrates  that  exceed  their  abil-
ty  to  metabolize  and  digest.  This  can  explain  the  small
umber  of  diagnosed  cases.
.  Case report
he  patient  is  a 6-months-old  Caucasian  male  infant  admit-
ed  in  our  hospital  for  chronic  diarrhea  and  failure  toonsanguineous  parents.  His  father  had  a  history  of  frequent
pisodes  of  diarrhea  in  youth,  which  were  never  the  subject
f  any  investigation.
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The  boy’s  medical  history  is  irrelevant  until  the  age  of
 months.  He  was  bottle-fed  with  a  hypoallergenic  for-
ula  and  was  thriving  until  4.5  months,  at  which  time
ood  diversiﬁcation  began  with  vegetables,  meat  and  fruit.
ome  days  after  this  dietary  modiﬁcation,  he  began  to  have
--10  episodes  per  day  of  non-bloody  watery  stools  and
oor  weight  gain.  No  diaper  rash  was  ever  observed.  For-
ula  changes  were  attempted  without  improvement.  He
as  admitted  in  another  hospital  at  the  age  of  5.5  months
or  evaluation  of  severe  diarrhea  and  malnutrition.
At  that  hospital,  he  underwent  an  extensive  study.  Stools
ere  negative  for  pathogenic  bacteria,  virus  and  parasites.
ecal  component  analysis  (neutral  fat,  fatty  acids,  muscle
bers,  leukocytes)  was  normal,  as  well  as  all  the  following
nvestigations:  blood  count,  liver  and  renal  proﬁle,  protein
lectrophoresis,  C-reactive  protein,  blood  immunoglobu-
ins,  anti-transglutaminase  antibodies,  allergens-speciﬁc  IgE
esting  for  baby  foods,  sweat  test,  thyroid  function  and
bdominal  ultrasound.  He  was  treated  empirically  with
etronidazole  and  ceftriaxone  without  improvement  and
as  subsequently  transferred  to  our  hospital.
Physical  examination  in  our  hospital  showed  an  alert,
ondysmorphic  infant  with  severe  reduction  in  muscle  mass
nd  subcutaneous  fat.  Besides  that,  physical  examination
as  non-informative.  Frequent  loose  watery  stools  were
oted.
Given  the  clinical  features  and  previous  laboratory  tests,
e  hypothesized  that  we  were  probably  facing  an  osmotic
iarrhea  due  to  CSID.  In  fact,  we  conﬁrmed  that  there  was  a
arked  decrease  in  stool  output  during  fasting  and  high  stool
smolality  (247.6  mOsm/kg).  He  underwent  a  glucose  toler-
nce  test  without  associated  symptoms  and  then  a sucrose
olerance  test  that  led  to  watery  diarrhea  within  hours  of  the
tudy.  Reducing  substances  were  measured  and  were  nega-
ive  during  both  tests;  no  acid  hydrolysis  of  feces  was  carried
ut  in  the  laboratory.  The  clinical  response  was  in  favor  of
SID.
During  the  hospitalization,  we  noticed  a  maculopapu-
ar  rash  evocative  of  cow’s  milk  protein  allergy.  Facing
wo  co-existing  diseases,  we  could  not  use  the  com-
on  protein  extensively  hydrolyzed  formulas  as  most  are
actose-free  and  contain  glucose  polymers  that  require
ucrase--isomaltase,  which  was  lacking  in  our  patient.  Thus,
he  infant  began  a  protein  extensively  hydrolyzed  formula
ontaining  lactose  (Althera®)  and  became  asymptomatic
ver  since  (no  diarrhea,  no  rash  and  favorable  weight  gain).
e  was  discharged  exclusively  fed  with  Althera®.  The  inten-
ional  re-exposure  to  a  formula  with  cow’s  milk  proteins
aused  a  relapse  of  cutaneous  lesions.  Likewise,  another
ucrose  tolerance  test  triggered  the  recurrence  of  the  diar-
hea.
At  the  age  of  7  months,  vegetables  and  fruit  were  rein-
roduced  and  diarrhea  occurred.  We  were  then  sure  that  it
as  a  case  of  CSID  and  we  were  facing  the  problem  of  how  to
anage  the  condition.  The  hypothesis  consisted  in  the  use
f  enzyme  replacement  sacrosidase,  the  adoption  of  a  free
ucrose  diet  or  the  addition  of  baker’s  yeast  to  the  diet.  We
ave  chosen  the  baker’s  yeast  and  the  infant  remains  com-
letely  asymptomatic,  has  excellent  weight  gain,  and  is  on
 normal  diet.  The  baker’s  yeast  is  added  to  the  diet  and  the
other  uses  the  minimum  amount  required  to  ensure  there
s  no  diarrhea.
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. Discussion
SID’s  diagnosis  waivers  complex  evaluation  exams,  but
equires  a  high  index  of  suspicion.  Infants  presenting  with
ersistent,  watery  diarrhea  after  weaning  and  the  introduc-
ion  of  starch  and  sucrose  in  the  diet  should  be  evaluated
or  CSID.  Diagnosis  can  be  achieved  with  a simple  strategy:
rst,  a  trial  of  fasting  (a  marked  decrease  in  stool  output
uring  fasting  suggests  an  osmotic  diarrhea),  then  a  glucose
olerance  test  in  order  to  exclude  the  very  rare  situation  of
lucose--galactose  intolerance,  followed  by  the  oral  sucrose
bsorption  test.  In  the  case  of  CSID,  the  ingestion  of  sucrose
but  not  glucose)  will  trigger  the  onset  of  diarrhea  within
ours.
Reducing  sugar  assay  is  used  to  detect  the  reducing
nds  of  carbohydrate  molecules.  Clinicians  should  note  that
linitest® yields  a  high  degree  of  false-negative  results,  as
appened  in  our  case.  Clinitest® is  only  positive  in  this  sit-
ation  for  maltose  or  dextrin-maltose  not  digested  due  to
somaltase  absence,  but  most  of  the  times  the  maltase-
lucoamylase  enzyme  can,  for  a  moderate  starch  amount,
eplace  that  activity.  So  its  result  may  not  provide  reli-
ble  information  especially  if  negative,  although  positivity
ay  be  regarded  as  a  useful  sign  to  conﬁrm  diagnosis.
ther  explanations  for  Clinitest®’s  false-negative  results
re  the  large  interval  between  fecal  collection  and  analy-
is  and  the  transport  at  room  temperature,  both  of  which
esult  in  the  growth  of  bacteria  that  consume  the  existing
ugars.  Moreover,  this  test  has  poor  sensitivity  from  dia-
er  stools  because  the  liquid  portion  of  the  stool,  which
ontains  the  water-soluble  sugars,  is  absorbed  by  the  dia-
er  ﬁlling.  A  handy  trick  to  circumvent  this  issue  is  to
lace  the  diaper  with  the  plasticized  waterproof  surface  in
ontact  with  the  skin,  so  that  the  liquid  component  is  not
bsorbed.
In  our  opinion,  molecular  genetic  test  for  mutation  in
SID  involves  signiﬁcant  costs  and  brings  no  additional  clin-
cal  beneﬁt  compared  with  simpler  diagnostic  procedures.
t  must  be  noted  that  more  than  25  mutations  have  been
dentiﬁed7 which  makes  it  very  difﬁcult  in  clinical  practice
o  establish  a  single  molecular  test  suitable  for  the  diagnosis
f  all  CSIDs.8
Another  important  discussion  point  concerns  the  thera-
eutic  options.  Enzyme  replacement  therapy  with  sacrosi-
ase  (Sucraid®)  facilitates  breakdown  of  sucrose  into  simpler
orms  for  absorption.  It  helps  to  relieve  the  gastrointesti-
al  symptoms  with  no  side  effects  and  allows  patients  to
aintain  a  normal  diet.4,9,10 Nonetheless,  sacrosidase  is  not
vailable  in  every  country  and  importing  it  may  be  quite
xpensive.
Baker’s  yeast  is  composed  of  lyophilized  Saccharomyces
erevisiae.  In  vitro, lyophilized  and  fresh  S.  cerevisiae
fresh  baker’s  yeast)  has  appreciable  sucrase  activity,  low
somaltase  and  maltase  activity  and  no  lactase  activity.6
east  sucrase  reduces  breath  hydrogen  excretion  in  patients
ith  CSID  who  are  given  a  sucrose  load  and  allows  most
atients  to  consume  a  sucrose-containing  diet.6,11 The
ucrase  activity  is  partially  inhibited  by  undiluted  gas-
ric  juice,  therefore  patients  with  CSID  can  ameliorate
he  sucrose  malabsorption  by  ingesting  a small  amount
f  viable  yeast  cells  on  a  full  stomach.6 Baker’s  yeast
ddition  to  the  diet  was  the  therapeutic  option  in  our
R1Congenital  sucrase--isomaltase  deﬁciency  
case,  with  the  advantage  of  being  inexpensive  and  easily
accessible.
The  coexistence  of  cow’s  milk  protein  allergy  implied  the
need  to  use  an  extensive  hydrolyzed  formula  with  lactose,
but  in  most  cases  of  CSID  a  formula  based  on  lactose  as
source  of  carbohydrate  is  effective  during  exclusive  bottle-
feeding.
4. Conclusion
This  typical  case  of  CSID  reinforces  the  important  role  of
careful  anamnesis  to  reach  the  diagnosis.  The  clinical  suspi-
cion,  after  being  hypothesized,  does  not  require  exhaustive
research.  Our  case  enhances  the  therapeutic  success  of  the
addition  of  baker’s  yeast  in  the  diet  as  an  effective  enzyme
replacement  therapy  for  patients  with  CSID.
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